CROSSJECT - Big improvement in the Gaïa social and environmental rating - Further proof of CROSSJECT’s commitment
November 07 2022 - 12:00PM
CROSSJECT - Big improvement in the Gaïa social and environmental
rating - Further proof of CROSSJECT’s commitment
Press Release
Big improvement in the
Gaïa social and environmental
rating
Further proof of CROSSJECT’s
commitment
Dijon, 7 November 2022 at 6pm (CET)
CROSSJECT (ISIN: FR0011716265; Ticker:
ALCJ), a specialty pharma company that is developing and will soon
be marketing a portfolio of drug / device combinations for use in
emergency situations, is proud to announce a significant
improvement in its Gaïa rating, with an overall score of 60/100 vs
46 last year. As a reminder, Gaïa Rating is an ESG rating agency
used by leading asset management companies in their management
process and investment decisions.
CROSSJECT first undertook to adopt an active
approach to achieve the best environmental, social and governance
(ESG) reporting standards in 2019, and can confirm significant new
improvements on all the criteria analysed by Gaïa, further to the
other awards received to date this year.
More than just compliance with constantly
changing standards, ESG management for CROSSJECT is clearly
embedded in its broader development strategy and operating
performance. As reflected in its commitment to the chemical
industry’s “Responsible Care” programme, CROSSJECT continues to
work tirelessly for continuous improvement in the areas of
environmental protection, health and safety.
Patrick Alexandre, Crossject CEO, said: “We are
very keen to improve our Gaïa score, which
objectively reflects our tireless efforts to achieve the best
social and environmental standards. Our decision to accept
benchmarking resonates perfectly with the spirit of our CSR
strategy: embrace requirements voluntarily before they
become
constraints!”
Contacts:
CrossjectPatrick Alexandre info@crossject.com |
Investor relations AELIUMJérôme
GACOIN +33 (0) 1 75 77 54 67 crossject@aelium.fr |
|
Press relations Buzz
& Compagnie Mélanie Voisard +33 (0)6 12 52 53
15melanie.voisard@buzzetcompagnie.com Christelle
Distinguin +33 (0)6 09 96 51
70christelle.distinguin@buzzetcompagnie.com |
About CROSSJECT• www.crossject.com
CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ;
LEI: 969500W1VTFNL2D85A65) is developing and is soon to market a
portfolio of drugs dedicated to emergency situations: epilepsy,
overdose, allergic shock, severe migraine and asthma attack. Thanks
to its patented needlefree self-injection system, Crossject aims to
become the world leader in self-administered emergency drugs. The
company has been listed on the Euronext Growth market in Paris
since 2014; it receives funding from the United States BARDA
(Biomedical Advanced Research and Development Authority) and from
Bpifrance.
Crossject (EU:ALCJ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Crossject (EU:ALCJ)
Historical Stock Chart
From Sep 2023 to Sep 2024